Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varespladib-methyl for Venomous Snakebites
NCT04996264Phase 2Completed
- Sponsor
- Ophirex
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in snakebite envenoming comparing Varespladib-methyl with Placebo (2 arms). Primary endpoint: Change in the Combined Pulmonary, Cardiovascular, Hematologic, Nervous System, and Renal Subscores of the Snakebite Severity Score at 9 hours. Started Aug 2021; status: completed.
02
Drugs
varespladib methyl
03
Conditions
snakebite envenoming
Beyond the preview
Go deeper on NCT04996264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996264.